740 related articles for article (PubMed ID: 34177932)
21. CAR T Cell Therapy for Solid Tumors.
Newick K; O'Brien S; Moon E; Albelda SM
Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
[TBL] [Abstract][Full Text] [Related]
22. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
[TBL] [Abstract][Full Text] [Related]
23. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Front Immunol; 2021; 12():738456. PubMed ID: 34721401
[TBL] [Abstract][Full Text] [Related]
24. Making CAR T Cells a Solid Option for Solid Tumors.
Schmidts A; Maus MV
Front Immunol; 2018; 9():2593. PubMed ID: 30467505
[TBL] [Abstract][Full Text] [Related]
25. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
26. [Not Available].
Rubio MT; Galaine J; Borg C; Daguindau É
Bull Cancer; 2018 Dec; 105 Suppl 2():S135-S146. PubMed ID: 30686352
[TBL] [Abstract][Full Text] [Related]
27. State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future?
Amorós-Pérez B; Rivas-Pardo B; Gómez Del Moral M; Subiza JL; Martínez-Naves E
Cells; 2024 Apr; 13(9):. PubMed ID: 38727261
[TBL] [Abstract][Full Text] [Related]
28. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives].
Nguyen S; Lacan C; Roos-Weil D
Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811
[TBL] [Abstract][Full Text] [Related]
29. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner J; Wickman E; DeRenzo C; Gottschalk S
Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
[TBL] [Abstract][Full Text] [Related]
30. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.
Shen L; Xiao Y; Tian J; Lu Z
Cancer Lett; 2022 Mar; 529():139-152. PubMed ID: 35007698
[TBL] [Abstract][Full Text] [Related]
31. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
32. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
33. The Role of Checkpoint Inhibitors and Cytokines in Adoptive Cell-Based Cancer Immunotherapy with Genetically Modified T Cells.
Gershovich PM; Karabelskii AV; Ulitin AB; Ivanov RA
Biochemistry (Mosc); 2019 Jul; 84(7):695-710. PubMed ID: 31509722
[TBL] [Abstract][Full Text] [Related]
34. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
35. Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors.
Mata M; Gottschalk S
Drugs; 2019 Mar; 79(4):401-415. PubMed ID: 30796733
[TBL] [Abstract][Full Text] [Related]
36. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
37. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
38. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
[TBL] [Abstract][Full Text] [Related]
39. CAR-Ts: new perspectives in cancer therapy.
Abrantes R; Duarte HO; Gomes C; Wälchli S; Reis CA
FEBS Lett; 2022 Feb; 596(4):403-416. PubMed ID: 34978080
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
